PCSK9 Inhibitors May Reduce Low Back Pain Risk: A Mendelian Randomization Study
en-GBde-DEes-ESfr-FR

PCSK9 Inhibitors May Reduce Low Back Pain Risk: A Mendelian Randomization Study

11/03/2026 Frontiers Journals
Low back pain is a leading global cause of disability, and the musculoskeletal impact of lipid-lowering drugs (e.g., statins, PCSK9 inhibitors) used for coronary heart disease (CHD) prevention has garnered attention. However, the causal relationship between lipid-lowering drug target inhibition and LBP risk remains unclear.
Here, a Mendelian randomization study investigated the association between inhibition of HMGCR, PCSK9, and NPC1L1 (key lipid-lowering targets) and LBP risk. Results showed PCSK9 inhibitors may reduce LBP risk, while HMGCR and NPC1L1 inhibitors had no significant association. Using CHD as a positive control, the study validated the reliability of findings, confirming known lipid-lowering effects on CHD risk.
This work provides the first genetic evidence for the musculoskeletal safety of HMGCR and NPC1L1 inhibitors, suggests potential LBP benefits of PCSK9 inhibitors, and opens new directions for exploring PCSK9 pleiotropy (e.g., anti-inflammatory, neuroprotective effects). The work entitled “Genetically proxied inhibition of lipid-lowering drug targets and risk of low back pain: A Mendelian randomization study” was published on Healthcare and Rehabilitation (published on October 16, 2025).
DOI
10.1016/j.hcr.2025.100053
https://doi.org/10.1016/j.hcr.2025.100053
Attached files
  • Image: Effects of HMGCR, PCSK9, and NPC1L1 inhibitors on coronary heart disease and low back pain.
11/03/2026 Frontiers Journals
Regions: Asia, China, North America, United States
Keywords: Science, Life Sciences

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...

  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by AlphaGalileo Terms Of Use Privacy Statement